Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma, Malignant 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Hepatocellular 1 Camurati-Engelmann Syndrome 1 Advanced Solid Tumors 1

Interventions

Fluorouracil 255 Leucovorin 224 Oxaliplatin 218 Irinotecan 206 Bevacizumab 200 Capecitabine 144 Cetuximab 136 Panitumumab 68 Folfox protocol 63 regorafenib 50 Colonoscopy 44 pembrolizumab 42 IFL protocol 39 Radiotherapy 32 Nivolumab 31 Drug Therapy 27 trifluridine tipiracil drug combination 26 Gemcitabine 24 Blood Specimen Collection 23 Chemotherapy, Adjuvant 20 Surveys and Questionnaires 19 Celecoxib 19 Surgical Procedures, Operative 16 durvalumab 15 Neoadjuvant Therapy 15 Cyclophosphamide 14 Cisplatin 14 aflibercept 13 Standard of Care 13 Pemetrexed 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Colorectal Neoplasms × ascrinvacumab × Clear all

NCT02116894 2019-03-14

REGAL-1

Duke University

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡